49 completed, 13 unknown, 2 not yet recruiting, 1 withdrawn. 35 Phase 1, 18 Not applicable, 5 Phase 2, 2 Early Phase 1, 2 Phase 3.
Follow Reference: new trials by email Literature Review of Reference trials Research Report on Reference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Sub-laminar and/or Interspinous Tethers to Prevent Proximal Junctional Kyphosis After Surgical Correction of Adult Spinal Deformity Tether strategy, Reference - Proximal Junctional Kyphosis | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 128 | 2026-10-22 | 2026-09-28 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers CKD-339, D311, D107 - Hypertension | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 76 | 2026-08-20 | 2026-08-06 |
| Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions ACC118-Test, Reference - Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Completed | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 48 | 2026-04-10 | 2026-08-10 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions Reference, Test - Bioequivalance | Phase 1 | Completed | ADIUM | 20 | 2025-03-18 | 2026-06-03 |
| A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201 UI059, UIC202201 - Gastro-Intestinal Disorder | Phase 1 | Unknown | Korea United Pharm. Inc. | 66 | 2024-07-03 | 2024-05-01 |
| A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects UI059, UIC202201 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 8 | 2023-10-08 | 2023-11-21 |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices LY3437943, Test, Reference - Healthy | Phase 1 | Completed | Eli Lilly and Company | 57 | 2023-08-29 | 2024-03-29 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| User Evaluation of BGM VGM77 subject, reference - Diabetes | Not applicable | Completed | Institut fur Diabetes Karlsburg GmbH | 106 | 2023-04-13 | 2023-09-14 |
| Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets Dapagliflozin 10 mg film-coated tablet, Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia - Healthy | Not applicable | Completed | Dexa Medica Group | 24 | 2023-03-08 | 2023-11-13 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions CKD-386(4) F1, CKD-386(4) F2, D013, D326, D337 - Hypertension and Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-09-23 | 2023-01-12 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions CKD-387, D484 - Endocrine, Nutritional and Metabolic Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-09-19 | 2024-05-03 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions CKD-387, D484 - Endocrine, Nutritional and Metabolic Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 37 | 2022-09-16 | 2024-05-03 |
| Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R DW5221, DW5221-R - Apetite Stimulants | Phase 1 | Completed | Daewon Pharmaceutical Co., Ltd. | 54 | 2022-07-01 | 2023-11-28 |
| Effects of Enhancers and Inhibitors on Absorption From Iron Supplements Reference, Ascorbic acid (AA) 500 mg, Ascorbic acid (AA) 80 mg - Iron-deficiency, Iron Deficiency Anemia | Not applicable | Completed | Swiss Federal Institute of Technology | 35 | 2022-06-20 | 2024-01-25 |
Showing 20 of 65. Sign in to see all of them.
Asthma (5) · Diabetes Mellitus, Type 2 (3) · Metabolic Diseases (3) · Psoriasis (3) · Arthritis, Rheumatoid (2) · Back Pain (2) · Cardiovascular Diseases (2) · Gastroesophageal Reflux (2) · Hepatitis B, Chronic (2) · Hypertension (2) · Metabolic Syndrome (2) · Musculoskeletal Diseases (2) · Obesity (2) · Osteoarthritis (2) · Acquired Immunodeficiency Syndrome (1)
Chong Kun Dang Pharmaceutical (13) · Respirent Pharmaceuticals Co Ltd. (9) · Lund University (4) · Almirall, S.A. (3) · Daewon Pharmaceutical Co., Ltd. (3) · Korea United Pharm. Inc. (3) · National Research Centre for the Working Environment, Denmark (3) · Dexa Medica Group (2) · ADIUM (1) · Alvogen Pine Brook LLC (1) · AstraZeneca (1) · Biocinese (1) · Centre Hospitalier Universitaire de Nīmes (1) · DLR German Aerospace Center (1) · Dong-A ST Co., Ltd. (1)
South Korea (20) · Greece (9) · Germany (6) · Denmark (3) · Canada (2) · China (2) · France (2) · Indonesia (2) · Sweden (2) · Switzerland (2) · United States (2) · Brazil (1) · Colombia (1) · Finland (1) · India (1)
Chrysoula Doxani, MD, MSc, PhD (5) · Anne Nilsson, PhD (2) · Christoph Willers, MD, MBA (2) · Lars L Andersen, PhD (2) · Ann-Charlotte Ewald (1) · Antoinie Guy Aya, MD (1) · Carmen Diaz-Toledo Trenado (1) · Carol Astbury, PhD (1) · Christoph Willers, MD (1) · Chrysoula Doxani, Dr. (1) · Dae-Kyeong Jun, M.D, Ph.D (1) · Daehyeok Kim, M.D, Ph.D (1)
PMID 21235752, PMID 25519844, PMID 26431123, PMID 26990559, PMID 27439370, PMID 28531784, PMID 29079551, PMID 30400947, PMID 30506361, PMID 33782738, PMID 35084526, PMID 38586120, PMID 38771476, PMID 41970000, PMID 42515774
2008 (1)